RESUMO
Occupational noise-induced hearing loss (ONIHL) is a prevalent occupational disorder that impairs auditory function in workers exposed to prolonged noise. However, serum microRNA expression in ONIHL subjects has not yet been studied. We aimed to compare the serum microRNA expression profiles in male workers of ONIHL subjects and controls. MicroRNA microarray analysis revealed that four serum microRNAs were differentially expressed between controls (n=3) and ONIHL subjects (n=3). Among these microRNAs, three were upregulated (hsa-miR-3162-5p, hsa-miR-4484, hsa-miR-1229-5p) and one was downregulated (hsa-miR-4652-3p) in the ONIHL group (fold change >1.5 and Pbon value <0.05). Real time quantitative PCR was conducted for validation of the microRNA expression. Significantly increased serum levels of miR-1229-5p were found in ONIHL subjects compared to controls (n=10 for each group; P<0.05). A total of 659 (27.0%) genes were predicted as the target genes of miR-1229-5p. These genes were involved in various pathways, such as mitogen-activated protein kinase (MAPK) signaling pathway. Overexpression of miR-1229-5p dramatically inhibited the luciferase activity of 3' UTR segment of MAPK1 (P<0.01). Compared to the negative control, HEK293T cells expressing miR-1229-5p mimics showed a significant decline in mRNA levels of MAPK1 (P<0.05). This preliminary study indicated that serum miR-1229-5p was significantly elevated in ONIHL subjects. Increased miR-1229-5p may participate in the pathogenesis of ONIHL through repressing MAPK1 signaling.
Assuntos
Perda Auditiva Provocada por Ruído/sangue , MicroRNAs/sangue , Proteína Quinase 1 Ativada por Mitógeno/análise , Doenças Profissionais/sangue , Exposição Ocupacional/efeitos adversos , Adulto , Biomarcadores/sangue , Estudos de Casos e Controles , Regulação da Expressão Gênica , Ontologia Genética , Perda Auditiva Provocada por Ruído/genética , Humanos , Masculino , MicroRNAs/genética , Pessoa de Meia-Idade , Doenças Profissionais/genética , Reação em Cadeia da Polimerase em Tempo RealRESUMO
Although a number of studies have been conducted to determine the association between vitamin D receptor (VDR) TaqI polymorphism and periodontitis in the Chinese population, this association remains elusive. To assess the influence of VDR TaqI polymorphism on the risk of periodontitis, a meta-analysis was performed in a Chinese population. Relevant studies were identified using the databases PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure, and Chinese Biology Medicine, through January 2016. Pooled odds ratios and 95% confidence intervals were used to assess the strength of the associations. This meta-analysis identified 9 studies, which included 1014 periodontitis cases and 907 controls. In both overall and subgroup analyses, VDR TaqI polymorphism was not associated with the risk of periodontitis. Cumulative analysis also suggested a lack of association between VDR TaqI polymorphism and the risk of periodontitis in the Chinese population. In conclusion, our meta-analysis showed that VDR TaqI polymorphism is not associated with the risk of periodontitis in the Chinese population. Further studies in other ethnic groups are required for definite conclusions.
Assuntos
Povo Asiático/genética , Periodontite/genética , Receptores de Calcitriol/genética , Alelos , Estudos de Casos e Controles , China , Predisposição Genética para Doença , Humanos , Razão de Chances , Polimorfismo de Nucleotídeo Único , Fatores de RiscoRESUMO
The tumor necrosis factor-alpha (TNF-α) G-308A polymorphism has been suggested to be a susceptibility factor for myocardial infarction (MI). However, differing results from various studies have led to controversial conclusions. Hence, we performed a meta-analysis to evaluate the association between TNF-α G-308A polymorphism and MI. Reported studies published before March 30, 2015 were included and analyzed from the PubMed and Embase databases. Study selection and data extraction were carried out independently by two authors. The odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the association between the selected variables using the Comprehensive Meta-Analysis v2.2 software. In total, 12 publications with 13 case-control studies consisting of 6037 cases and 7262 controls were included in our meta-analysis. The overall results showed that there was no significant association between TNF-α G-308A polymorphism and MI risk [A vs G: OR = 1.18, 95%CI = 0.94-1.48; AA vs GG: OR = 1.23, 95%CI = 0.74-2.05; GA vs GG: OR = 1.22, 95%CI = 0.98-1.51; (GA+AA) vs G: OR = 1.21, 95%CI = 0.96-1.54; AA vs (GG+GA): OR = 1.16, 95%CI = 0.72-1.88]. However, when subgroup analysis was performed according to the stages of MI, results indicated that there was a significant association between TNF-α G-308A polymorphism and the risk of acute MI. Other subgroup analyses revealed no significant associations. Current evidence suggests that TNF-α G-308A polymorphism may be associated with increased risk for acute MI.
Assuntos
Predisposição Genética para Doença , Infarto do Miocárdio/genética , Polimorfismo de Nucleotídeo Único , Fator de Necrose Tumoral alfa/genética , Estudos de Casos e Controles , Expressão Gênica , Humanos , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/patologia , Razão de Chances , Fatores de RiscoRESUMO
Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate of 5%. Biomarkers for the early detection of pancreatic cancer are urgently needed. Transforming growth factor-beta1 (TGF-ß1) is elevated in the tissues and plasma of patients with PDAC. However, no studies systemically report prognostic significance of plasma TGF-ß1 levels in PDAC. In the present study, we assessed the prognostic significance of serum TGF-ß levels in patients with PDAC. TGF-ß levels were determined in serum from 146 PDAC patients, and 58 patients with benign pancreatic conditions. Regression models were used to correlate TGF-ß levels to gender, age, stage, class, and metastasis. Survival analyses were performed using multivariate Cox models. Serum levels of TGF-ß1 distinguished PDAC from benign pancreatic conditions (P<0.001) and healthy control subjects (P<0.001). Serum levels of TGF-ß also distinguished tumor stage (P=0.002) and lymph node metastasis (P=0.001). High serum levels of TGF-ß1 were significantly correlated with reduced patient survival. Multivariate analysis revealed that TGF-ß1, lymph node metastasis and tumor stage were independent factors for PDAC survival. Our results indicate that serum TGF-ß1 may be used as a potential prognostic marker for PDAC.
Assuntos
Biomarcadores Tumorais/sangue , Carcinoma Ductal Pancreático/sangue , Neoplasias Pancreáticas/sangue , Fator de Crescimento Transformador beta1/sangue , Carcinoma Ductal Pancreático/diagnóstico , Carcinoma Ductal Pancreático/secundário , Humanos , Estimativa de Kaplan-Meier , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/secundário , Prognóstico , Estudos Retrospectivos , Sensibilidade e EspecificidadeRESUMO
Breast cancer (BC) is the most widespread cause of cancer-related deaths in women. Many published studies have assessed the association between the glutathione S-transferase P1 (GSTP1) rs1695 polymorphism and BC risk. However, the effect of the GSTP1 rs1695 polymorphism on BC risk has remained controversial. Therefore, this meta-analysis was conducted to obtain a comprehensive estimation of this association. A total of 20,615 cases and 20,481 controls from thirty-six case-control trials were extracted from an online literature survey. The meta-analysis indicated that the GSTP1 rs1695 A>G polymorphism did not contribute to the susceptibility of BC when the overall population was considered. However, intriguingly, this polymorphism was significantly associated with increased risk of BC in Asian women [GG vs AA: odds ratio (OR) = 1.4, 95% confidence interval (CI): 1.06-1.88, P = 0.02; AG vs AA: OR = 1.08, 95%CI = 1.00-1.16, P = 0.05; GG/AG vs AA: OR = 1.11, 95%CI = 1.04-1.19, P = 0.00]. Moreover, a subgroup analysis based on the source of control groups showed a marked increase in BC susceptibility in hospital-based control subjects (GG vs AA: OR = 1.28, 95%CI = 1.10-1.48, P= 0.00; GG vs AG/AA: OR = 1.22, 95%CI = 1.06-1.41, P = 0.00; GG/AG vs AA: OR = 1.10, 95%CI = 1.02-1.18, P = 0.00). In conclusion, our study indicated that the GSTP1 rs1695 A>G polymorphism was correlated with elevated BC risk in Asian women. Our results must be validated with further research.
Assuntos
Neoplasias da Mama/enzimologia , Neoplasias da Mama/genética , Glutationa S-Transferase pi/genética , Povo Asiático/genética , Estudos de Casos e Controles , Feminino , Predisposição Genética para Doença , Glutationa S-Transferase pi/metabolismo , Humanos , Polimorfismo de Nucleotídeo Único , Fatores de RiscoRESUMO
Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate of 5%. Biomarkers for the early detection of pancreatic cancer are urgently needed. Transforming growth factor-beta1 (TGF-β1) is elevated in the tissues and plasma of patients with PDAC. However, no studies systemically report prognostic significance of plasma TGF-β1 levels in PDAC. In the present study, we assessed the prognostic significance of serum TGF-β levels in patients with PDAC. TGF-β levels were determined in serum from 146 PDAC patients, and 58 patients with benign pancreatic conditions. Regression models were used to correlate TGF-β levels to gender, age, stage, class, and metastasis. Survival analyses were performed using multivariate Cox models. Serum levels of TGF-β1 distinguished PDAC from benign pancreatic conditions (P<0.001) and healthy control subjects (P<0.001). Serum levels of TGF-β also distinguished tumor stage (P=0.002) and lymph node metastasis (P=0.001). High serum levels of TGF-β1 were significantly correlated with reduced patient survival. Multivariate analysis revealed that TGF-β1, lymph node metastasis and tumor stage were independent factors for PDAC survival. Our results indicate that serum TGF-β1 may be used as a potential prognostic marker for PDAC.
Assuntos
Humanos , Neoplasias Pancreáticas/sangue , Biomarcadores Tumorais/sangue , Carcinoma Ductal Pancreático/sangue , Fator de Crescimento Transformador beta1/sangue , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/secundário , Prognóstico , Estudos Retrospectivos , Sensibilidade e Especificidade , Carcinoma Ductal Pancreático/diagnóstico , Estimativa de Kaplan-MeierRESUMO
Serum liver enzyme levels are often used effectively for the evaluation of nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the associations between serum liver enzyme levels and risks for NAFLD in over 8000 cases in a large-scale analysis. A cross-sectional survey with multiple stages and random samplings was performed from May 2007 to May 2009 on 8102 workers at Tongji University. A questionnaire was given, assessments of physical measurements, plasma glucose, lipid profiles, and liver enzymes were made, and real-time liver ultrasounds conducted. The prevalence of NAFLD in Tongji University was 22.2%. It was higher in males than in females (P = 0.0023). The body mass index, waist-to-hip ratio, serum total triglycerides, serum total cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) values were all higher in the NAFLD group than in the control group. For moderate and severe NAFLD patients, the ALT, AST and GGT values were significantly increased, high density lipoprotein cholesterol was decreased, and drinking much, heavy entertainment and less exercise were more prevalent (P < 0.001). There were strong correlations between serum liver enzyme levels and NAFLD (P < 0.001), with GGT being a more sensitive marker for NAFLD than ALT or AST. ALT and GGT were independent predictors for NAFLD, and GGT was a better predictor than ALT for NAFLD.
Assuntos
Fígado/enzimologia , Fígado/patologia , Hepatopatia Gordurosa não Alcoólica/enzimologia , Hepatopatia Gordurosa não Alcoólica/etiologia , Adulto , Estudos de Casos e Controles , Feminino , Humanos , Testes de Função Hepática , Masculino , Hepatopatia Gordurosa não Alcoólica/diagnóstico , Hepatopatia Gordurosa não Alcoólica/epidemiologia , Prevalência , Fatores de Risco , Índice de Gravidade de DoençaRESUMO
A genome-wide association study revealed that a single nucleotide polymorphism, CLPTM1L - rs401681 (G>A), located at the 5p15.33 locus was significantly associated with increased risk of various cancers; however, its association with lung cancer is currently inconclusive. In order to explore the relationship between this polymorphism and lung cancer risk more precisely, we performed a meta-analysis of eight eligible studies involving 9935 cases and 11,261 controls. The pooled odds ratio (OR) and the 95% confidence interval (CI) were calculated using a fixed- or random-effect models. Results indicated that this polymorphism was significantly associated with lung cancer risk in all genetic models (GA vs GG: OR = 0.88, 95%CI = 0.83-0.94; AA vs GG: OR = 0.81, 95%CI = 0.70-0.93; AA/GA vs GG: OR = 0.86, 95%CI = 0.81-0.91; AA vs GA/GG: OR = 0.86, 95%CI = 0.76-0.99). An analysis stratified by ethnicity and source of controls revealed a significantly decreased risk among European groups and population-based studies in all genetic models, and among Asian populations only in the dominant model comparison. Additionally, in a subgroup analysis by histology type, the CLPTM1L rs401681 polymorphism was found to significantly decrease the risks of both adenocarcinoma and squamous cell carcinoma of the lung in all genetic models. In conclusion, our study indicated that the CLPTM1L - rs401681 (G>A) polymorphism was significantly associated with decreased lung cancer risk, especially among European populations. Due to some minor limitations, our findings should be confirmed in further studies.
Assuntos
Predisposição Genética para Doença , Neoplasias Pulmonares/genética , Proteínas de Membrana/genética , Proteínas de Neoplasias/genética , Polimorfismo de Nucleotídeo Único , Alelos , Estudos de Casos e Controles , Genótipo , Humanos , Neoplasias Pulmonares/epidemiologia , Razão de Chances , Viés de Publicação , RiscoRESUMO
The global features of trimethylations of histone 3 at lysine 9 (H3K9me3) have been well studied in recent years; however, most of these studies were performed in mammalian cell lines. In this study, we generated genome-wide maps of H3K9me3 of the human heart and spleen using chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) technology. We examined the global patterns of H3K9me3 in both tissues and found that modifications were closely associated with tissue-specific expression, function, and development. In addition, we found that 169 genes displayed significant H3K9me3 differences between the heart and spleen. Among these genes, 64 were heart-H3K9me3-specific, 87 genes were spleen-H3K9me3-specific, and 18 were shared in both heart- and spleen-H3K9me3. In conclusion, we observed significant differences in H3K9me3 in the heart and spleen, which may help to explain epigenetic differences between these tissues. Such novel findings highlight the significance of H3K9me3 as a potential biomarker or promising target for epigenetic-based disease treatment.
Assuntos
Cromatina/genética , Epigenômica , Genoma Humano , Histonas/genética , Animais , Histona Desmetilases/genética , Histonas/metabolismo , Humanos , Metilação , Miocárdio/metabolismo , Análise de Sequência com Séries de Oligonucleotídeos , Baço/metabolismoRESUMO
INTRODUÇÃO: O aumento da expectativa de vida da população e o risco de sangramento com o uso de trombolíticos têm permitido que pacientes casa vez mais idosos com infarto agudo do miocárdio sejam tratados pela intervenção coronária percutânea (ICP) primária. Analisamos os resultados hospitalares da ICP primária em pacientes com idade >ou igual a 80 anos. Métodos: No período de janeiro de 2002 a outubro de 2008, foram realizadas 4.788 ICPs, sendo 428 ICPs primárias. Destas, 34 foram em pacientes com idade > igual a 80 anos. Resultados: O sexo feminino (47,1 por cento vs. 27,7 por cento = 0,017), a classe funcional Killip IV (11,8 por cento vs. 4,1; P = 0,002) e o fluxo coronário TIMI 2/3 pré-ICP (60 por cento vs. 44,4 por cento; P = 0,032) foram mais frequentes nos idosos. Tabagismo (44,9 por cento vs. 8 por cento; P = 0,001)e uso de inibidores...
BACKGROUND: Improvements in life expectancy of the overall population and the risk of bleeding with thrombolytics have enabled very elderly patients with acute myocardial infarction to be treated by primary percutaneous coronary intervention (PCI). We analyzed the primary PCI in-hospital results in patients > 80 years of age. METHOD: From January 2002 to October 2008, 4,788 PCIs were performed, of which 428 were primary PCIs. Of these, 34 were performed in patients > 80 years of age and 394 in patients < 80 years of age. RESULTS: Females (47.1% vs. 27.7%; P = 0.017), Killip IV functional class (11.8% vs. 4.1%; P = 0.002) and pre-procedure TIMI 2/3 flow (60% vs. 44.4%; P = 0.032) were more frequent in elderly patients. Smoking (44.9% vs. 8%; P < 0.001) and use of glycoprotein IIb/IIIa inhibitors (32.5% vs. 11.7%; P = 0.04) were prevalent in the group < 80 years of age. There were no significant differences for door-to-balloon time (117.4 ± 125.7 minutes vs. 179.3 ± 169.8 minutes; P = 0.095), use of stents (91.2% vs. 98.2%; P = 0.78), or drug-eluting stents (0 vs. 2.8%; P = 0.067) and thrombus aspiration devices (11.7% vs. 12.2%; P = 0.65). Angiographic success rate was equal between the groups (97.1% vs. 96.5%; P > 0.99), but patients > 80 years old had a higher mortality rate (11.8% vs. 2.3%; P = 0.014). Reinfarction, stroke, major vascular complications and acute renal failure were similar between groups. CONCLUSION: PCI usually presents high angiographic success and low complication rates, reinforcing its role as a method of choice for reperfusion in the acute phase of myocardial infarction. Very elderly patients (> 80 years of age) have higher mortality rates, possibly due to the greater comorbidity in this group.
Assuntos
Humanos , Masculino , Feminino , Idoso , Angioplastia Coronária com Balão/métodos , Angioplastia Coronária com Balão , Infarto do Miocárdio/complicações , Infarto do Miocárdio/diagnóstico , Fatores de RiscoRESUMO
Organ transplantation success depends principally on avoiding rejection, a purpose almost accomplished with immunosuppressant therapy. Nevertheless, drug side effects have promoted the search for other mechanisms to restrain alloresponses. T-regulatory cells (Treg) might exert that function. Campath 1H (C1H) induces Treg proliferation in the period subsequent to T-cell depletion following C1H administration. In the present study, the status of Treg and de novo HLA antibody production was determined posttransplantation when T-cell repopulation had been completed. In 14 patients, the following parameters were analyzed: renal function, rejection, Treg, panel-reactive antibody (PRA), and HLA antibodies. Patient and graft survivals were 100%. At the moment of Treg determination (20 months following transplant) the mean tacrolimus level was 8.4 ng/mL. One patient experienced an antibody-mediated rejection at 15 months after transplantation while having 3.2% Treg, with excellent treatment responses. Mean leukocyte and lymphocyte counts were 5752 and 1183 cells/mm(3); the mean peripheral blood percentage of Treg of 7.1% +/- 5.9% was not different from that observed in subjects without induction (mean 5.5% +/- 2.5%). Three patients (21%) showed Treg greater than 8.0%. In seven patients, we compared Treg at 4 and 20 months posttransplant, observing a decline from a mean of 19.9% to 5.9% (P = .05). In seven recipients, posttransplant PRA was determined; five of them became "de novo" sensitized, three with a mean class I PRA of 16% and two with a mean class II PRA of 37%. In conclusion, patient and graft survivals were excellent, mean Treg percentage was not elevated with results lower than in the early posttransplant period. Rejection incidence was negligible. Late "de novo" sensitization occurred in 70% showing that B cell-mediated alloresponses were only partially controlled among recipients induced with C1H even when associated with sustained anticalcineurin treatment.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Anticorpos Antineoplásicos/uso terapêutico , Transplante de Rim/imunologia , Linfócitos T Reguladores/imunologia , Adulto , Alemtuzumab , Anticorpos Monoclonais Humanizados , Azatioprina/uso terapêutico , Complexo CD3/sangue , Antígenos CD4/sangue , Cadáver , Ciclosporina/uso terapêutico , Feminino , Sobrevivência de Enxerto/imunologia , Antígenos HLA/imunologia , Humanos , Imunossupressores/uso terapêutico , Doadores Vivos , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Doadores de TecidosRESUMO
A library of phage-displayed human single-chain Fv (scFv) antibodies was selected against the human amyloid-beta peptide (Abeta42). Two new anti-Abeta42 phage-displayed scFvs antibodies were obtained, and the sequences of their V(H) and Vkappa genes were analyzed. A synthetic peptide based on the sequence of Ig heavy chain (V(H)) complementarity-determining region (HCDR3) of the clone with the highest recognition signal was generated and determined to bind to Abeta42 in ELISA. Furthermore, we showed for the first time that an HCDR3-based peptide had neuroprotective potential against Abeta42 neurotoxicity in rat cultured hippocampal neurons. Our results suggest that not only scFvs recognizing Abeta42 but also synthetic peptides based on the V(H) CDR3 sequences of these antibodies may be novel potential candidates for small molecule-based Alzheimer's disease (AD) therapy.
Assuntos
Peptídeos beta-Amiloides/farmacologia , Regiões Determinantes de Complementaridade/metabolismo , Região Variável de Imunoglobulina/metabolismo , Fragmentos de Peptídeos/farmacologia , Animais , Anticorpos/análise , Anticorpos/metabolismo , Células Cultivadas , Regiões Determinantes de Complementaridade/análise , Humanos , Região Variável de Imunoglobulina/análise , Ligação Proteica/fisiologia , Ratos , Ratos WistarRESUMO
A single-chain fragment variable (scFv) antibody library displayed on phage was constructed using spleen cells from mice immunized with human amyloid-beta peptide (Abeta42). This first anti-Abeta42 scFv immune antibody library was selected against human Abeta42. A number of positive clones were obtained, and sequences of VH and Vkappa genes were analyzed using ExPASy and BLAST computer tools. This analysis revealed that only two unique clones with identical VH and Vkappa complementarity determining region (CDR) (except HCDR2) and identical germline genes were selected, indicating that oligoclonal immune response was occurring in Abeta42-immunized mice. Abeta42-specific scFv antibodies selected from this first immune anti-Abeta42 phage antibody library may be an important tool for the development of therapeutic molecules for Alzheimer's disease (AD).
Assuntos
Peptídeos beta-Amiloides/imunologia , Bacteriófago M13/imunologia , Epitopos/imunologia , Fragmentos de Imunoglobulinas/isolamento & purificação , Região Variável de Imunoglobulina/isolamento & purificação , Fragmentos de Peptídeos/imunologia , Biblioteca de Peptídeos , Animais , Bacteriófago M13/genética , Ensaio de Imunoadsorção Enzimática , Genes de Imunoglobulinas , Vetores Genéticos , Fragmentos de Imunoglobulinas/biossíntese , Fragmentos de Imunoglobulinas/genética , Cadeias Pesadas de Imunoglobulinas/genética , Região Variável de Imunoglobulina/biossíntese , Região Variável de Imunoglobulina/genética , Cadeias kappa de Imunoglobulina/genética , Camundongos , Análise de Sequência de DNARESUMO
The antiemetic effect of tropisetron was studied in 97 cancer patients (67 men, 30 women) receiving cisplatin in doses of 75 mg/m2 or higher. On 279 chemotherapy cycles studied (max 6 per patient) 5 mg of tropisetron was administered once a day i.v on day 1 and p.o. on days 2 to 6. Efficacy preventing vomiting and nausea was measured in 24 hour period as: complete control O episodes, major control 1 to 2 episodes, minor control 3 to 4 episodes and no control 5 or more episodes. Satisfactory vomiting control (complete and major) was 69%, 63%, 82%, 88%, 96% and 96% in days 1 to 6 of cycle 1. Satisfactory nausea control (complete and major) for the same days was 70%, 66%, 72%, 85%, 92% and 97%. Similar data was obtained for the subsequent cycles. Complete vomiting control was obtained in 47%, 35%, 56%, 72%, 81% and 84% and for nausea in 42%, 39%, 48%, 64%, 81% and 87%. 19 patients presented adverse effects (19.6%). Only 2 headache episodes had a definite relation with the antiemetic drug. 12 patients discontinued the medication; 6 due to drug inefficacy, 2 to illness unrelated to the drug, 1 to lack of collaboration, and 3 due to other reasons. We conclude that tropisetron allows satisfactory control of acute and delayed vomiting in a high percentage of patients treated with high doses of cisplatin. The drug does not have significant secondary effects. Tropisetron administration in only one daily dose implies an evident advantage and a treatment cost reduction.
Assuntos
Antieméticos/uso terapêutico , Antineoplásicos/efeitos adversos , Indóis/uso terapêutico , Náusea/prevenção & controle , Neoplasias/tratamento farmacológico , Vômito/prevenção & controle , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Tropizetrona , Vômito/induzido quimicamenteRESUMO
The first results of the management of adult non-Hodgkin lymphoma according to the National Protocol are reported. 164 pts (71 female and 93 male), aged 50 (range 15 to 79 years) were included. 89 pts had lymphomas with intermediate, 34 with low and 24 with high grade malignancy. 65% had advanced stages (III and IV). In the low grade malignancy group 38% were in complete remission and actuarial survival at 20 months was 80%. In the intermediate grade group, stages I and II the corresponding values were 79 and 85%; in the intermediate grade stages III and IV, 58 and 69%, and in the high grade group 61 and 77%. Bone marrow toxicity and infections were the main complications. 32 pts have died, 10 of them with drug toxicity complications.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma não Hodgkin/tratamento farmacológico , Adolescente , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Bleomicina/administração & dosagem , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Esquema de Medicação , Etoposídeo/administração & dosagem , Feminino , Humanos , Ifosfamida/administração & dosagem , Leucovorina/administração & dosagem , Linfoma não Hodgkin/patologia , Linfoma não Hodgkin/radioterapia , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Mitoguazona/administração & dosagem , Estadiamento de Neoplasias , Prednisona/administração & dosagem , Procarbazina/administração & dosagem , Vincristina/administração & dosagemRESUMO
We report preliminary results of treatment of Hodgkin disease according to the National Protocol on Antineoplastic Drugs. 37 males and 22 females with a median age of 34 years (range 16 to 76) were treated. Patients with stages I or II received radiotherapy alone or chemotherapy (C-MOPP) followed by radiotherapy. Patients with stages III or IV received radiotherapy and chemotherapy or alternating courses of C-MOPP and ABVD. Complete remission was observed in 74% of 39 patients completing full therapy. Complete remission was more common in patients with nodular sclerosis without B symptoms and under 45 years of age. Actuarial survival at 22 months was 79%, significantly higher for patients with nodular sclerosis compared to patients with lymphocytic depletion. Different treatments in patients at stages I and II or III and IV gave comparable results. Complications included infection with the Chickenpox-Zoster virus, pneumonia and fever of unknown origin. Mortality was associated to older age, complications of treatment or failure to comply with therapy.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doença de Hodgkin/tratamento farmacológico , Análise Atuarial , Adolescente , Adulto , Idoso , Bleomicina/administração & dosagem , Terapia Combinada , Doxorrubicina/administração & dosagem , Esquema de Medicação , Feminino , Doença de Hodgkin/mortalidade , Doença de Hodgkin/radioterapia , Humanos , Masculino , Mecloretamina/administração & dosagem , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Procarbazina/administração & dosagem , Prognóstico , Vimblastina/administração & dosagem , Vincristina/administração & dosagemRESUMO
We report preliminary results from a national protocol for treatment of acute lymphoblastic leukemia. 44 patients, 15 females and 29 males with age range 15 to 65 years (median 27) were treated and followed for 22 months. Complete remission was observed in 33 (77%) of 43 patients with a known induction result. Remission was 100%, 86% and 61% for low (3), medium or high risk patients (p = 0.03). Complete remission occurred more often in patients with WBC less than 35,000 or granulocyte counts greater than 100. Actuarial survival rate at 22 months was 60% overall and 100%, 64% and 50% for the low, intermediate and high risk groups, respectively (NS). Death occurred in 16 patients, 5 during induction, 3 during complete remission, 6 during relapse and 2 after induction failure. Infections were the main cause of death in all groups.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Análise Atuarial , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Programas Nacionais de Saúde , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Indução de Remissão , Risco , Taxa de SobrevidaRESUMO
After a follow up of 22 months we report results of treatment on 44 patients (22 males), aged 16 to 63 years, with acute non lymphoblastic leukemia. Complete remission was obtained in 22 patients. This was significantly more frequent in patients under 40 years of age with white cell counts under 35,000 and without metabolic complications nor disseminated intravascular coagulation before treatment. Delaying chemotherapy for 5 days after diagnosis was also associated to a better prognosis. Overall actuarial survival rate was 37% at 15 months, 55% for those experiencing a first remission. A total of 25 patients [corrected] have died, 15 during induction of therapy, 7 after complete remission and 3 after failure of induction. Infections are the main cause of death during induction, with a high lethality for sepsis (33%) and pneumonia (40%).
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia Mieloide Aguda/tratamento farmacológico , Análise Atuarial , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Feminino , Humanos , Infecções/etiologia , Leucemia Mieloide Aguda/mortalidade , Masculino , Pessoa de Meia-Idade , Neutropenia/induzido quimicamente , Prognóstico , Indução de Remissão , Taxa de Sobrevida , Trombocitopenia/induzido quimicamenteRESUMO
The role of prostaglandins (Pg) in the pathogeny of periodontal disease is analyzed. For that purpose, 92 samples of gingivae were taken to the same number of patients (48 women and 44 men) aged 17-74 years, and were clinically classified according to Löe gingival index. Presence of prostaglandins was determined by thin layer chromatography. Presence or absence of PgE2 was related to sex, age, Löe gingival index and degree of inflammatory infiltrated. Although correlation between Löe gingival index and degree of inflammatory infiltrate has not an exactly correspondence, the first one offers a useful initial clinical orientation. To patients with higher degree of inflammation corresponded higher PgE2 concentrations. Possibility of using prostaglandin inhibiting drugs in the treatment of periodontal disease is stated.